Page 23 - Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

12. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, 23. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of us-
Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. İnfliximab tekinumab in the treatment of patients with psoriasis and concurrent
therapy in a patient with Crohn’s disease and chronic hepatitis B virus hepatitis B or C. Br J Dermatol. 2013;169(6):1295-1303.
infection. Inflamm Bowel Dis 2004;10(5):701-2. 24. Kurt H, Battal İ, Memikoğlu O, Yeşilkaya A, Tekeli E. The spectrum of
13. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlots- seropositivity of HAV, HBV, HCV according to age and sex in healthy
ky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in population in Ankara. Viral Hepatit Derg 2003;8:88-96.
patients with chronic hepatitis B or C. J Rheumatol 2004;31(1):107-9. 25. Bozkurt H, Kurtoglu MG, Bayram Y, Kesli R, Berktas M. Distribution of
14. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with pso- hepatitis C prevalence in individuals according to their age level in
riatic arthritis and concurrent hepatitis C virus infection: report of 3 Eastern Turkey. Eur J Gastroenterol Hepatol 2008;20(12):1249.
cases. J Am Acad Dermatol 2004;51(4):580-4. 26. Yildirim B, Barut S, Bulut Y, Yenişehirli G, Ozdemir M. Seroprevalen-
15. Parke FA, Reveille JD . Anti-tumor necrosis factor agents for rheuma- ce of hepatitis B and C viruses in the province of Tokat in the Black
toid arthritis in the setting of chronic hepatitis C infection. Arthritis Sea region of Turkey: A population-based study. Turk J Gastroenterol
Rheum 2004;51(5):800-4. 2009;20(1):27-30.
16. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour 27. Tozun N, Ozdogan O, Cakaloglu Y. Seroprevalence of hepatitis B and C
necrosis factor agents in patients with chronic hepatitis C infection: a virus infections and risk factors in Turkey: a fieldwork TURHEP study.
systematic review. Rheumatology (Oxford) 2011;50(9):1700-11. Clin Microbiol Infect. 2015;21(11):1020-6.
17. Sebastiani M, Milazzo L, Atzeni F. Italian consensus recommendations 28. Yılmaz N, Karadağ Ö, Kimyon G, Yazıcı A, Yılmaz S, Kalyoncu U, et al.
for the management of hepatitis C infection in patients with rheuma- Prevalence of hepatitis B and C infections in rheumatoid arthritis and
toid arthritis. Mod Rheumatol 2019;29(6):895-902. ankylosing spondylitis: A multicenter countrywide study. Eur J Rheu-
18. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et matol 2014;1(2):51-4.
al. 2012 update of the 2008 American College of Rheumatology (ACR) 29. Mok CC. Hepatitis B and C infection in patients undergoing biologic
recommendations for the use of disease-modifying anti-rheumatic and targeted therapies for rheumatic diseases. Best Practice & Rese-
drugs and biologics in the treatment of rheumatoid arthritis (RA). arch Clinical Rheumatology 2018;32:767-80.
Arthritis Care Res (Hoboken) 2012;64(5):625-39. 30. Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, et al. Safety
19. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α in- and efficacy of anti-tumor necrosis factors α in patients with psoriasis
hibitors and chronic hepatitis C: A comprehensive literature review. and chronic hepatitis C. World J Clin Cases 2016;4(2):49-55.
World J Gastroenterol 2013;19(44):7867-73. 31. Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F.
20. Nagashima T, Maruyama A, Kamata Y, Minota S. Unchanged serum Timing strategies of direct-acting antivirals and biologics administ-
viral load and liver function during tocilizumab treatment in a patient ration in HCV-infected subjects with ınflammatory bowel diseases.
with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Front Pharmacol 2017;8:867.
Int 2012;32(7):2231-2. 32. European Association for the Study of the Liver. EASL Recommendati-
21. Dragonas C, Ehrenstein B, Fleck M. Tocilizumab treatment in a patient ons on Treatment of Hepatitis C 2018. J Hepatol 2018.
suffering from rheumatoid arthritis and concomitant chronic hepati- 33. Karadağ Ö, Kaşifoğlu T, Özer B, Kaymakoğlu S, Kuş Y, İnanç M, et al.
tis C infection. Rheumatology (Oxford) 2012;51(8):1520-1. Romatolojik hastalarda biyolojik ilaç kullanım öncesi (viral) hepatit
22. Mahajan TD, Hooker R, Maher L, Brown G, Reimold A. Abatacept the- tarama kılavuzu. RAED Dergisi 2015;7(1):28-32.
rapy for rheumatoid arthritis in the setting of hepatitis C infection. J
Clin Rheumatol 2010;16(7):332-4.

13